

CASE REPORT

Investigation of Mutations in Exon 14 of *SH3TC2* Gene and Exon 7 of *NDRG1* Gene in Iranian Charcot-Marie-Tooth Disease Type 4 (CMT4D) Patients

How to Cite This Article: Moosavi R¹, Jahangir Soltani N², Houshmand M³. Investigation of Mutations in Exon 14 of *SH3TC2* Gene and Exon 7 of *NDRG1* Gene in Iranian Charcot-Marie-Tooth Disease Type 4 (CMT4D) Patients. *Iran J Child Neurol*. Spring 2020; 14(2): 93-100

Rahmaneh Sadat MOOSAVI MSc¹,

Niloofer JAHANGIR SOOLTANI MSc²,

Massoud HOUSHMAND PhD⁴

1. Science and Research Branch of Islamic Azad University, Islamic Republic of Iran.

2. Department of Medical Biotechnology, National Institute of Genetic Engineering and Biotechnology, Tehran, Iran.

3. Department of Medical Biotechnology National Institute of Genetic Engineering and Biotechnology, Tehran, Iran.

4. Research Center, Knowledge University, Erbil, Kurdistan Region, Iraq.

Corresponding Author:

Houshmand M. PhD

Department of National Institute of Genetic Engineering and Biotechnology, Tehran, Iran.

Email: massoudh@nigeb.ac.ir

Received: 26-Nov-2017

Accepted: 07-Mar-2018

Last Revised: 16- Feb -2019

Abstract

Objectives

Charcot-Marie-tooth disease type 4 (CMT4D) is an autosomal recessive form of Charcot-Marie-tooth disease with an earlier age of onset and greater severity, compared to other types of this disease. CMT4C and CMT4D are the most prevalent subtypes in Mediterranean countries due to the higher rate of consanguineous marriage. In this study, we aimed to identify p.R148X mutation in *NDRG1* gene and p.R1109X mutation in *SH3TC2* gene (responsible for CMT4D and CMT4C, respectively) and to investigate other possible nucleotide changes in exon 14 of *SH3TC2* gene and exon 7 of *NDRG1* gene in an Iranian population.

Materials & Methods

A total of 24 CMT4D patients, who were referred to Iran Special Medical Center, were clinically and electrophysiologically evaluated in this study. DNA was extracted from the patients' blood samples. Next, polymerase chain reaction (PCR) assay was carried out, and the products were sequenced and analyzed in FinchTV software.

Results

None of the target mutations were found in this study. Sequencing of *SH3TC2* gene showed SNP rs1025476 (g.57975C>T) in 21 (87.5%) patients, including 7 homozygous and 14 heterozygous individuals.

Conclusion

Despite the high rate of mutations in some populations, it seems that they are very rare in Iranian CMT4D patients. Regarding the association of SNP rs1025476 with CMT4D, further assessments are needed to reach a better understanding of genetic markers and their genetic features and to propose better diagnostic and treatment plans for the Iranian population.

Keywords: *SH3TC2* gene; *NDRG1* gene; CMT4D; Charcot-Marie-tooth disease; Iran

Introduction

Charcot-Marie-tooth disease (CMTD) is recognized as the most common inherited neuromuscular disorder. It is a gradually progressive disease with an approximate prevalence of 1/2500 people (1). Symptoms of this disease include muscle weakness and atrophy, which may appear from the first to the third decade of life. Genetically, it is a heterogeneous disease with an autosomal dominant, autosomal recessive (AR), or X-linked inheritance (2).

In recent decades, classification of CMTD has become more complex (3), and its inheritance modes (2, 4, 5) and involved nerves vary in each type. Responsible mutations have been identified in more than 80 genes. Generally, different mutations cause different modes of inheritance (6-8). Charcot-Marie-tooth disease type 4 (CMT4D) is an AR form of demyelinating CMTD. This disease is characterized by an early onset, usually before the age of 2-3 years, and rapid clinical progression, which leads to more distal limb deformities (9, 10). In recent studies, it has been suggested that mutations in *SH3TC2* gene, which are responsible for CMT4C, are the most common contributing factors for CMT4D not only in the Mediterranean region, but also in European and North American countries (9). *SH3TC4* gene, also known as *KIAA1985* gene, encodes a protein, which is expressed in the peripheral nerves of Schwann cells (11, 12). This protein is required for proper myelination and integrity of the node of Ranvier in the peripheral nervous system (6). According to recent studies, lack of *SH3TC1* gene in recycling endosomes is an underlying molecular defect, leading to CMT4C (13). This gene includes 17 encoding exons and is located on chromosome 5 (5q32). It is clear that a defect in this gene causes

myelination defects.

NDRG1 gene mutation leads to the development of hereditary motor and sensory neuropathy Lom type, also known as CMT4D (14). CMT4D is characterized by Schwann cell dysfunction, associated with early and severe axonal loss due to axon-glial interaction failure (9, 14). Recent studies have concluded that impaired Schwann cell trafficking fails to meet the considerable demands of nerve growth and may be involved in the pathogenetic mechanism of *NDRG1* deficiency. One of the mutations is located on codon 148 of *NDRG1* gene (15, 16). *NDRG1* gene, which is ubiquitously expressed, contributes to growth arrest, cell differentiation, and possibly signaling protein shuttling between the cytoplasm and the nucleus. This gene is located on chromosome 8q24.3, with a high level of expression in Schwann cells (14).

In the present study, we aimed to investigate CMT4C and CMT4D with an AR mode of inheritance, which show greater severity and earlier age of onset, compared to other types of CMTD (9, 17). Different mutations are responsible for CMT4D. Generally, ten different subclasses have been recognized so far, each responsible for CMT4A-J (9). Since ARCMT is more frequent in countries with a high rate of consanguineous marriage (17), we aimed to analyze two mutations of p.R148X in *NDRG1* gene and p.R1109X in *SH3TC2* gene, which can both create stop codons, responsible for CMT4D and CMT4C, respectively. Considering the higher rate of consanguineous marriage in some regions of Iran, we may assume that these mutations play a significant role in this population.

Early onset of CMTD subtypes and their severe phenotypes, which are associated with severe

polyneuropathy and specific deformations, encouraged us to collect more information about these diseases in the Iranian population. In this study, we aimed to investigate the presence of p.R148X mutation in *NDRG1* gene and p.R1109X mutation in *SH3TC2* gene and to identify other possible mutations and polymorphisms in 24 Iranian CMT4D patients, who were referred to Iran Special Medical Center. (No 4, Ostadnejatolahi St. Tehran, Iran.)

Materials & Methods

In this survey, a total of 24 patients (14 males and 10 females; mean age=8.7 years), who were referred to a medical center, were studied under the supervision of neurologists and clinical geneticists for accurate diagnosis of CMT4D. Most patients presented with early-onset demyelinating neuropathy, distal muscular hypotrophy, scoliosis, and other basic features of the disease. No mutation in previously screened *GDAP1* gene, which is another responsible gene for CMT4D (9), was found in the patients. Both parents of all probands were healthy, and informed consent was obtained from the parents or guardians of the patients.

A blood sample (2 cc) was collected from each patient and preserved in a falcon tube, containing EDTA at -20°C until DNA extraction. Genomic DNA was extracted using Genpajooan DNA Extraction Kit (Iran) and stored at -20°C. Target DNA fragments of *NDRG1* exon 7 and *SH3TC2* exon 14 were amplified by polymerase chain reaction (PCR) assay with forward and reverse primers (primer sequences and PCR conditions are available upon request). Appropriate synthesis of PCR products was evaluated using 1.5% Agarose gel electrophoresis.

The search for mutations (p.R148X mutation in *NDRG1* gene and p.R1109X mutation in *SH3TC2*

gene) was conducted via Sanger sequencing of PCR products, using the ABI3700 tool (Kosar Kavosh Fanavaron Co., Iran). FinchTV software was also used for analyzing the sequences in order to identify mutations. The sequences were blasted in NCBI website (<http://www.ncbi.nlm.nih.gov/blast>) and compared with normal sequences. The length of PCR products for analyzing exon 14 of *SH3TC2* gene was 331 bp. To ensure the authenticity of the products, they were compared with a 100-bp DNA ladder via 1.5% Agarose gel electrophoresis. In addition, the length of PCR product was 170 bp for exon 7 of *NDRG1* gene, which was compared with the 50-bp DNA ladder.

Results

Sequence analysis indicated that p.R148X mutation of *NDRG1* gene and p.R1109X mutation of *SH3TC2* gene (both responsible for CMT4D) were not present in the target regions and that the sequences were normal. Based on the sequence analysis of *SH3TC2* gene (exon 14), 21 out of 24 probands (87.5%) showed g.57975C>T variant (c.3327+70C>T), including 14 (58%) heterozygous and 7 (29%) homozygous individuals for this nucleotide mutation (Figure 1). The three remaining patients showed normal sequences.

Analysis of *NDRG1* sequences (exon 7) indicated that all 24 probands had normal sequences in the evaluated region and that no nucleotide changes were observed. Some sequence analyses were performed for assessment by reverse primers. To ensure the results of sequencing, four samples were randomly considered for assessment by reverse primers (two samples for *SH3TC2* gene and two samples for *NDRG1* gene). The results showed the authenticity of previous results obtained from analyses using forward primers.




Figure 1. (a) Homozygous g.57975C>T variant in exon 14 of *SH3TC2* gene and (b) heterozygous g.57975C>T variant of *SH3TC2* gene

Discussion

According to previous studies, AR-CMTD can be found in people of all races. As multiple studies have indicated, the prevalence of mutations varies in different populations. It is noticeable that in Western countries, the prevalence of AR-CMTD is significantly lower than the dominant form of CMTD (12). Evidence suggests that the prevalence of AR-CMTD is about 10% in Europe and 30-50% in Mediterranean countries (18).

According to a previous study on recessive CMTD, conducted in 2014 in Germany, involvement of genes, such as *GDAP*, *HINT1*, *SH3TC2*, and *NDRG1*, was estimated at 10.9%, 10.3%, 7.5%, and 6.3%, respectively (19). In a previous study on a gypsy population, involvement of these genes, including p.R148X mutation in *NDRG1* gene, was reported in nearly 4.46% of AR-CMTD cases (19). On the other hand, in a study on another gypsy population in Bulgaria, the high frequency of p.R148x mutation was reported, and mutation carriers accounted for 10-16% of the population (20).

The presence of p.R1109X mutation in *SH3TC2* gene has not been examined separately, and different results have been reported regarding the overall contribution of this mutation. CMT4D (mutation in *NDRG1* gene), a common form of AR-CMTD in gypsy populations, has been reported in European countries. It is the most frequent peripheral

neuropathy among Serbian gypsies (21, 22), whereas in Spain, the prevalence rate is different. In addition, CMT4C (mutation in *SH3TC2* gene) is the most common form of CMT4D in the gypsy population of Spain, followed by CMT4G and CMT4D (23).

In another study from Spain on 29 gypsy individuals with recessive CMT4D, the prevalence of *SH3TC2* gene mutation (CMT4C) was 57.14%, the prevalence of *HK1* gene mutation (CMT4G) was 25%, and the prevalence of CMT4D was 17.86% (21). Furthermore, a study from South of Italy on 197 CMTD patients revealed that the prevalence of *SH3TC2* gene was only 2% in the general population in the same period (24). Moreover, a study performed in 2016 in Germany showed that the overall prevalence of *SH3TC2* gene was 2.7% in patients with demyelinating CMTD (25).

Although the rate of these mutations is very low in most countries, a high rate has been reported in gypsy populations, as mentioned earlier, which may be attributed to their specific features and genetic differences (20, 26, 27). According to previous studies, the gypsy population was influenced by the bottleneck effect due to the migration of their ancestors from India to Europe. Also, research on genetic markers show that gypsies migrated from India to countries, such as Pakistan, Iran, Turkey, South Armenia, and Europe (28); therefore, genetic merging may have occurred in some traits and

genes in these countries.

Evidence suggests that pathogenic mutations responsible for AR myasthenic syndromes were inherited from the common ancestry history of gypsy, Indian, and Pakistani populations (29).

Therefore, the incidence of these mutations in the Iranian population is highly expected considering the prevalence of consanguineous marriage in some parts of Iran. Based on studies from Turkey and Spain, one of the target mutations in our study (p.R1109X) had a very distant ancestral origin; this finding shows that mutations occurred in new generations. Moreover, estimation of allelic age indicates that p.R1109X mutation in *SH3TC2* gene was related to the bottleneck effect and probably occurred 225 years ago (between the late 18th century and early 19th century) (21). According to previous studies, these mutations mostly occurred in isolated populations with a high rate of consanguineous marriage.

Despite the presence of these mutations in other populations from some Mediterranean and European countries, such as Spain and Czechoslovakia, no mutations were found in our study; accordingly, the studied mutations are very rare in non-specific populations. Differences between the findings of our study and studies on other populations can be attributed to differences in the structure, ethnic background, and origin of Iranian population. Considering the limitations in the availability of CMT4 probands, lack of the studied mutations in our population may indicate that other mutations in *SH3TC2* and *NDRG1* genes or other causative genes are involved in CMT4C and CMT4D due to the heterogenic features of the disease.

Analysis of the intronic region near exon 14 of *SH3TC2* gene indicated rs1025476 SNP

(g.57975C>T). It should be noted that this SNP was found in a study on a Turkish control population (30). Moreover, since this SNP was found in the majority of proband genes, this mutation may be one of the genetic characteristics of the studied population; such findings can be useful for a better understanding of the genomic features of Iranian population. To clarify the association between this SNP and CMTD, further assessments using case-control studies with a higher number of patients and greater funding are necessary to overcome the limitations of previous studies.

In Conclusion, By applying more comprehensive methods, such as next generation sequencing, in future studies, we can have a more comprehensive view about this issue. Overall, our findings contribute to the available genetic data regarding CMT4D in the Iranian population. Further genetic analysis can provide a better diagnostic approach for this disease through identification of rare or common genetic features in each specific population.

Acknowledgement

We would like to thank all patients and their families for their sincere cooperation. We would like to thank all the participants for their blood donation to the Medical Genetics Department at the Special Medical Centre, Tehran, Iran. This study was partially supported by Iran National Science Foundation. The authors would like to express their utmost gratitude and appreciation to the “National Institute for Genetic Engineering and Biotechnology (NIGEB) of Tehran”, Project 187.

Authors' contributions

Rahmaneh Sadat Moosavi (MSc) substantial contributions to conception and design, acquisition

of data, to analyse and interpretation of data, and writing the manuscript.

Niloofar Jahangir Soltani (MSc) participation of revising and gave final approval of version to be submitted.

Massoud Houshmand (Ph.D) contributions to conception and design, participation of revising and gave final approval of version to be submitted.

Conflicts of Interest

None Declare

References

1. Murakami T, Garcia CA, Reiter LT, Lupski JR. Charcot-Marie-Tooth disease and related inherited neuropathies. *Medicine*. 1996;75(5):233-50.
2. Georgiou D-M, Nicolaou P, Chitayat D, Koutsou P, Babul-Hirji R, Vajsar J, et al. A novel GDAP1 mutation 439delA is associated with autosomal recessive CMT disease. *Canadian journal of neurological sciences*. 2006;33(3):311-6.
3. Reilly MM. Classification of the hereditary motor and sensory neuropathies. *Current opinion in neurology*. 2000;13(5):561-4.
4. Ng AA, Logan AM, Schmidt EJ, Robinson FL. The CMT4B disease-causing phosphatases Mtmr2 and Mtmr13 localize to the Schwann cell cytoplasm and endomembrane compartments, where they depend upon each other to achieve wild-type levels of protein expression. *Human molecular genetics*. 2013;22(8):1493-506.
5. Scherer SS, Wrabetz L. Molecular mechanisms of inherited demyelinating neuropathies. *Glia*. 2008;56(14):1578-89.
6. Arnaud E, Zenker J, Charles A-SdP, Stendel C, Roos A, Medard J-J, et al. SH3TC2/KIAA1985 protein is required for proper myelination and the integrity of the node of Ranvier in the peripheral nervous system (vol 106, 17528, 2009). *Proceedings of the National Academy of Sciences of the United States of America*. 2010;107(34): 305-15.
7. Harding A, Thomas P. The clinical features of hereditary motor and sensory neuropathy types I and II. *Brain: a journal of neurology*. 1980;103(2):259-80.
8. P Drew A, P Blair I, A Nicholson G. Molecular genetics and mechanisms of disease in distal hereditary motor neuropathies: insights directing future genetic studies. *Current molecular medicine*. 2011;11(8):650-65.
9. Tazir M, Bellatache M, Nouioua S, Vallat JM. Autosomal recessive Charcot-Marie-Tooth disease: from genes to phenotypes. *Journal of the Peripheral Nervous System*. 2013;18(2):113-29.
10. Baets J, Deconinck T, De Vriendt E, Zimoń M, Yperzele L, Van Hoorenbeeck K, et al. Genetic spectrum of hereditary neuropathies with onset in the first year of life. *Brain*. 2011;134(9):2664-76.
11. Stendel C, Roos A, Kleine H, Arnaud E, Özçelik M, Sidiropoulos PN, et al. SH3TC2, a protein mutant in Charcot-Marie-Tooth neuropathy, links peripheral nerve myelination to endosomal recycling. *Brain*. 2010;133(8):2462-74.
12. Gabreëls-Festen A, van Beersum S, Eshuis L, LeGuern E, Gabreëls F, van Engelen B, et al. Study on the gene and phenotypic characterisation of autosomal recessive demyelinating motor

- and sensory neuropathy (Charcot-Marie-Tooth disease) with a gene locus on chromosome 5q23-q33. *Journal of Neurology, Neurosurgery & Psychiatry*. 1999;66(5):569-74.
13. Roberts RC, Peden AA, Buss F, Bright NA, Latouche M, Reilly MM, et al. Mistargeting of SH3TC2 away from the recycling endosome causes Charcot-Marie-Tooth disease type 4C. *Human molecular genetics*. 2009;19(6):1009-18.
 14. Kalaydjieva L, Gresham D, Gooding R, Heather L, Baas F, De Jonge R, et al. N-myc downstream-regulated gene 1 is mutated in hereditary motor and sensory neuropathy-Lom. *The American Journal of Human Genetics*. 2000;67(1):47-58.
 15. Gabrikova D, Mistrik M, Bernasovska J, Bozikova A, Behulova R, Tothova I, et al. Founder mutations in NDRG1 and HK1 genes are common causes of inherited neuropathies among Roma/Gypsies in Slovakia. *Journal of applied genetics*. 2013;54(4):455-60.
 16. Ricard E, Mathis S, Magdelaine C, Delisle MB, Magy L, Funalot B, et al. CMT4D (NDRG1 mutation): genotype-phenotype correlations. *Journal of the Peripheral Nervous System*. 2013;18(3):261-5.
 17. Vallat J, Magdelaine C, Sturtz F, Tazir M. Autosomal recessive forms of Charcot-Marie-Tooth disease. *Current neurology and neuroscience reports*. 2004;4(5):413-9.
 18. Saporta AS, Sottile SL, Miller LJ, Feely SM, Siskind CE, Shy ME. Charcot-Marie-Tooth disease subtypes and genetic testing strategies. *Annals of neurology*. 2011;69(1):22-33.
 19. Zimoń M, Battaloğlu E, Parman Y, Erdem S, Baets J, De Vriendt E, et al. Unraveling the genetic landscape of autosomal recessive Charcot-Marie-Tooth neuropathies using a homozygosity mapping approach. *neurogenetics*. 2015;16(1):33-42.
 20. Morar B, Azmanov DN, Kalaydjieva L. Roma (Gypsies): genetic studies. *eLS*. 2013.
 21. Claramunt R, Sevilla T, Lupo V, Cuesta A, Millán J, Vilchez J, et al. The p. R1109X mutation in SH3TC2 gene is predominant in Spanish Gypsies with Charcot-Marie-Tooth disease type 4. *Clinical genetics*. 2007;71(4):343-9.
 22. Keckarevic Markovic MP, Dackovic J, Mladenovic J, Milic-Rasic V, Kecmanovic M, Keckarevic D, et al. An algorithm for genetic testing of Serbian patients with demyelinating Charcot-Marie-Tooth. *Genetic testing and molecular biomarkers*. 2013;17(1):85-7.
 23. Sevilla T, Martínez-Rubio D, Márquez C, Paradas C, Colomer J, Jaijo T, et al. Genetics of the Charcot-Marie-Tooth disease in the Spanish Gypsy population: the hereditary motor and sensory neuropathy-Russe in depth. *Clinical genetics*. 2013;83(6):565-70.
 24. Manganelli F, Tozza S, Pisciotta C, Bellone E, Iodice R, Nolano M, et al. Charcot-Marie-Tooth disease: frequency of genetic subtypes in a Southern Italy population. *Journal of the Peripheral Nervous System*. 2014;19(4):292-8.
 25. Rudnik-Schöneborn S, Tölle D, Senderek J, Eggermann K, Elbracht M, Kornak U, et al. Diagnostic algorithms in Charcot-Marie-Tooth neuropathies: experiences from a German genetic laboratory on the basis of 1206 index patients. *Clinical genetics*. 2016;89(1):34-43.

26. Navarro C, Teijeira S. Neuromuscular disorders in the Gypsy ethnic group. A short review. *Acta myologica: myopathies and cardiomyopathies: official journal of the Mediterranean Society of Myology/edited by the Gaetano Conte Academy for the study of striated muscle diseases*. 2003;22(1):11-4.
27. Kalaydjieva L, Hallmayer J, Chandler D, Savov A, Nikolova A, Angelicheva D, et al. Gene mapping in Gypsies identifies a novel demyelinating neuropathy on chromosome 8q24. *Nature genetics*. 1996;14(2):214-7.
28. Kalaydjieva L, Morar B, Chaix R, Tang H. A newly discovered founder population: the Roma/Gypsies. *Bioessays*. 2005;27(10):1084-94.
29. Morar B, Gresham D, Angelicheva D, Tournev I, Gooding R, Guerguelcheva V, et al. Mutation history of the roma/gypsies. *The American Journal of Human Genetics*. 2004;75(4):596-609.
30. Senderek J, Bergmann C, Stendel C, Kirfel J, Verpoorten N, De Jonghe P, et al. Mutations in a gene encoding a novel SH3/TPR domain protein cause autosomal recessive Charcot-Marie-Tooth type 4C neuropathy. *The American Journal of Human Genetics*. 2003;73(5):1106-19.